Compare VRA & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | PRLD |
|---|---|---|
| Founded | 1982 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.6M | 69.1M |
| IPO Year | 2010 | 2020 |
| Metric | VRA | PRLD |
|---|---|---|
| Price | $3.20 | $2.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.00 | $4.00 |
| AVG Volume (30 Days) | ★ 1.1M | 495.7K |
| Earning Date | 12-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $324,296,000.00 | $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 250.00 |
| 52 Week Low | $1.39 | $0.61 |
| 52 Week High | $4.00 | $4.22 |
| Indicator | VRA | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 71.33 | 63.48 |
| Support Level | $2.10 | $2.37 |
| Resistance Level | $2.50 | $3.00 |
| Average True Range (ATR) | 0.18 | 0.28 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 99.79 | 76.55 |
Vera Bradley Inc designs women's handbags, travel items, and accessories. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The majority of revenue is from the Vera Bradley Direct segment.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.